becotatug vedotin

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
becotatug vedotin

GtoPdb Ligand ID: 14392

Synonyms: MRG-003 | MRG003 | Tsune Miyu® (China)

becotatug vedotin is an approved drug

Compound class: Antibody

Comment: Becotatug vedotin (MRG003) is a fully human anti-EGFR antibody-drug conjugate [5]. The payload is the synthetic antimitotic agent/tubulin polymerization inhibitor monomethyl auristatin E (MMAE). Becotatug vedotin was designed for potential antitumour activity.

References
1. Blair HA. (2026) Becotatug Vedotin: First Approval. Drugs, [Epub ahead of print]. [PMID:41787195]
2. Han F, Lv X, Zhou YJ, He Q, Guo Y, Xiang YQ, Shu XL, Pan SM, Qu SH, Zhang P et al.. (2026) Becotatug vedotin, MRG003, in previously treated recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase IIa trial. Med,: 101029 [Epub ahead of print]. [PMID:41720100]
3. Jing R, Zhi X, Shao L. (2026) Approvals by the China NMPA in 2025. Nat Rev Drug Discov, [Epub ahead of print]. [PMID:41688808]
4. Qiu MZ, Zhang Y, Guo Y, Guo W, Nian W, Liao W, Xu Z, Zhang W, Zhao HY, Wei X et al.. (2022) Evaluation of Safety of Treatment With Anti-Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors: A Phase 1 Nonrandomized Clinical Trial. JAMA Oncol, 8 (7): 1042-1046. [PMID:35511148]
5. Yu J, Fang T, Yun C, Liu X, Cai X. (2022) Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers. Front Mol Biosci, 9: 847835. [PMID:35295841]

References

1. Blair HA. (2026)
Becotatug Vedotin: First Approval.
Drugs, [Epub ahead of print]. [PMID:41787195]

2. Han F, Lv X, Zhou YJ, He Q, Guo Y, Xiang YQ, Shu XL, Pan SM, Qu SH, Zhang P et al.. (2026)
Becotatug vedotin, MRG003, in previously treated recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase IIa trial.
Med,: 101029 [Epub ahead of print]. [PMID:41720100]

3. Jing R, Zhi X, Shao L. (2026)
Approvals by the China NMPA in 2025.
Nat Rev Drug Discov, [Epub ahead of print]. [PMID:41688808]

4. Qiu MZ, Zhang Y, Guo Y, Guo W, Nian W, Liao W, Xu Z, Zhang W, Zhao HY, Wei X et al.. (2022)
Evaluation of Safety of Treatment With Anti-Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors: A Phase 1 Nonrandomized Clinical Trial.
JAMA Oncol, 8 (7): 1042-1046. [PMID:35511148]

5. Yu J, Fang T, Yun C, Liu X, Cai X. (2022)
Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers.
Front Mol Biosci, 9: 847835. [PMID:35295841]